Trial reportNature communications2024
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.
Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03654833 (Mesothelioma Stratified Therapy), which is not on this map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma
Who cites it
26 citing papers in PubMed.
- Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.Gut microbes · 2026Review
- Effect of dietary chenodeoxycholic acid on fat deposition and intestinal health in Wenchang chickens.Poultry science · 2026Article
- Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.Nature communications · 2026Article
- Microbial reprogramming of immunogenic cell death: a new paradigm in tumor immunotherapy.Cancer biology & medicine · 2026Review
- Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.Nature genetics · 2026Article
- Review
- Gut microecology empowers cancer immunotherapy: commensal microbiota-mediated mechanisms and translational prospects of PD-1/PD-L1 therapy.Cancer biology & medicine · 2026Review
- The Multi-dimensional Mechanisms and Transformation Prospects of the Intratumoral Microbiota-Arginine Metabolism Axis in Tumor Progression and Immune Regulation.International journal of medical sciences · 2026Review
- From biology to therapy: current standards and emerging strategies in pleural mesothelioma.Frontiers in oncology · 2026Review
- Review
- Salivary microbiome in patients with benign prostatic hyperplasia: altered composition and its association with prostate-specific antigen.BMC microbiology · 2025Article
- EMT and cancer: what clinicians should know.Nature reviews. Clinical oncology · 2025Review
- Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review.Medicina (Kaunas, Lithuania) · 2025Review
- Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors.NPJ biofilms and microbiomes · 2025Article
- Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Review
- Integration of multi-omics approaches in exploring intra-tumoral heterogeneity.Cancer cell international · 2025Review
- CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma.Journal of experimental & clinical cancer research : CR · 2025Article
- Pleural mesothelioma.Nature reviews. Disease primers · 2025Review
- Gut microbiota shapes cancer immunotherapy responses.NPJ biofilms and microbiomes · 2025Review
- Causal effect of gut microbiota on the risk of cancer and potential mediation by inflammatory proteins.World journal of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors.
Min Zhang *National Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Aleksandra Bzura *National Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Essa Y Baitei *National Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Zisen Zhou *Department of Informatics, University of Leicester, Leicester, UK.ORCID 0000-0001-6122-5586
Jake B Spicer *National Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.ORCID 0000-0003-2842-7412
Charlotte PoileNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Jan RogelNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Amy BransonLeicester Clinical Trials Unit, University of Leicester, Leicester, UK.
Amy KingDepartment of Oncology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Shaun BarberLeicester Clinical Trials Unit, University of Leicester, Leicester, UK.
Tamihiro KamataNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.ORCID 0000-0002-2032-9300
Joanna DzialoNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.ORCID 0000-0001-6083-7687
James HarberHarry Perkins Institute of Medical Research and The University of Western Australia Centre for Cancer Research, Perth, WA, Australia.
Alastair GreystokeNorthern Centre for Cancer Care, Newcastle, UK.ORCID 0000-0001-9168-0387
Nada NusratNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Daniel FaulknerNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.ORCID 0000-0003-3438-7330
Qianqian SunNovogene Corporation, Beijing, China.
Luke NolanUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
Jens C HahneNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Molly ScotlandDepartment of Oncology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Harriet WalterNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.ORCID 0000-0003-2618-711X
Liz DarlisonMesothelioma, Leicester, UK.
Bruno MorganDepartment of Radiology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Amrita BajajDepartment of Radiology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Cassandra BrookesLeicester Clinical Trials Unit, University of Leicester, Leicester, UK.
Edward J HolloxDepartment of Genetics and Genome Biology, University of Leicester, Leicester, UK.ORCID 0000-0002-0115-2298
Dominika LubawskaDepartment of Genetics and Genome Biology, University of Leicester, Leicester, UK.
Maymun JamaNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Gareth GriffithsUniversity of Southampton Clinical Trials Unit, Southampton, UK.
Apostolos NakasDepartment of Cardiothoracic Surgery, University Hospitals of Leicester NHS Trust, Leicester, UK.
Kudzayi KutywayoDepartment of Cardiothoracic Surgery, University Hospitals of Leicester NHS Trust, Leicester, UK.
Jin-Li LuoBioinformatics and Statistics Analysis Hub, University of Leicester, Leicester, UK.
Astero KlampatsaInstitute of Cancer Research, Sutton, UK.ORCID 0000-0003-0572-502X
Andrea CooperDepartment of Respiratory Sciences, University of Leicester, Leicester, UK.ORCID 0000-0001-6050-3863
Koirobi HalderDepartment of Respiratory Sciences, University of Leicester, Leicester, UK.
Peter Wells-JordanNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Huiyu ZhouDepartment of Informatics, University of Leicester, Leicester, UK.
Frank DudbridgeDepartment of Health Sciences, University of Leicester, Leicester, UK.ORCID 0000-0002-8817-8908
Anne ThomasNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Catherine Jane RichardsDepartment of Pathology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Catrin PritchardNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK.
Hongji YangDepartment of Informatics, University of Leicester, Leicester, UK.ORCID 0000-0001-6561-3631
Michael BarerDepartment of Respiratory Sciences, University of Leicester, Leicester, UK.
Dean A FennellNational Institute for Health Research Biomedical Research Centre & Cancer Research UK Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK. df132@leicester.ac.uk.ORCID 0000-0001-7373-1312
Funding
Cancer Research UK (CRUK) C10604/A25151
Abstract
Malignant mesothelioma is a rare tumour caused by asbestos exposure that originates mainly from the pleural lining or the peritoneum. Treatment options are limited, and the prognosis is dismal. Although immune checkpoint blockade (ICB) can improve survival outcomes, the determinants of responsiveness remain elusive. Here, we report the outcomes of a multi-centre phase II clinical trial (MiST4, NCT03654833) evaluating atezolizumab and bevacizumab (AtzBev) in patients with relapsed mesothelioma. We also use tumour tissue and gut microbiome sequencing, as well as tumour spatial immunophenotyping to identify factors associated with treatment response. MIST4 met its primary endpoint with 50% 12-week disease control, and the treatment was tolerable. Aneuploidy, notably uniparental disomy (UPD), homologous recombination deficiency (HRD), epithelial-mesenchymal transition and inflammation with CD68
Indexed as
Antibodies, Monoclonal, HumanizedB7-H1 AntigenBevacizumabGastrointestinal MicrobiomeImmune Checkpoint InhibitorsAgedFemaleHumansLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMiddle AgedTreatment OutcomeTumor MicroenvironmentVascular Endothelial Growth Factor AAntibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenBevacizumabCD274 protein, humanImmune Checkpoint InhibitorsVascular Endothelial Growth Factor A
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03654833ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.